<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Umbralisib (United States: Withdrawn from market): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Umbralisib (United States: Withdrawn from market): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Umbralisib (United States: Withdrawn from market): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="130745" href="/d/html/130745.html" rel="external">see "Umbralisib (United States: Withdrawn from market): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F56565773"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Umbralisib Indications Withdrawn</span>
<span class="collapsible-date">Updated June 2022</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has withdrawn its approval for Ukoniq (umbralisib) due to safety concerns. Health care providers should stop prescribing Ukoniq and switch patients to alternative treatments. Patients currently taking Ukoniq should be informed of the increased risk of death seen in the UNITY-CLL clinical trial and advised to stop taking the medicine. In limited circumstances in which a patient may be receiving benefit from Ukoniq, TG Therapeutics plans to make it available under expanded access.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-approval-lymphoma-medicine-ukoniq-umbralisib-withdrawn-due-safety-concerns&amp;token=7tSuzMBL9E0UYF0xgKdfpT80wintpULGH9YCByrHP%2BbXXWkHlS2D2XpZyGvzsRFobOlCgr%2F1tn93bWW4OySTo9ltWvJ%2B2DR29xtKov10MWs%2BM1V7jzunpU42XtK011XXMOJHyenjYXz0oVuZ%2BXtLeA%3D%3D&amp;TOPIC_ID=130727" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-approval-lymphoma-medicine-ukoniq-umbralisib-withdrawn-due-safety-concerns</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55480831"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ukoniq [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55469353"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Phosphatidylinositol 3-Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F55485049"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Updated findings from a clinical trial demonstrated safety concerns for umbralisib and as a result the FDA determined the risks of umbralisib treatment outweigh benefits; due to this, the manufacturer has voluntarily withdrawn umbralisib from the market.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i> Administer <i>P. jirovecii</i> pneumonia prophylaxis during umbralisib therapy; consider antiviral prophylaxis to prevent cytomegalovirus (CMV) infection, including CMV reactivation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b28971b-5a9a-4dc4-bcdd-b523341b6807">Follicular lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Follicular lymphoma, relapsed or refractory: Oral:</b> 800 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Zinzani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Zinzani.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0308a072-e082-45a6-b8f2-5be32d172b33">Marginal zone lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Marginal zone lymphoma, relapsed or refractory: Oral:</b> 800 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Zinzani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Zinzani.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed, administer as soon as remembered if &lt;12 hours until the next dose. If vomiting occurs, do not take an additional dose; continue with the next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F55485051"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Kidney function estimated by the Cockcroft-Gault equation.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F55485052"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin ≤ ULN and AST &gt; ULN <b>or</b> total bilirubin &gt;1 to 1.5 times ULN and any AST): No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) or severe (total bilirubin &gt;3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">AST or ALT &gt;5 to &lt;20 times ULN: Withhold umbralisib until recovery to &lt;3 times ULN, then resume at a reduced dose (see "Dosing: Adjustment for Toxicity" for dose reduction levels).</p>
<p style="text-indent:-2em;margin-left:4em;">AST or ALT &gt;20 times ULN: Discontinue umbralisib.</p></div>
<div class="block dot drugH1Div" id="F55485053"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Umbralisib Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Dose level</p></th>
<th align="center">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial (usual) dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">800 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">First dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Subsequent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue umbralisib if unable to tolerate 400 mg once daily.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Umbralisib Recommended Dose Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Dose modification</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Hematologic toxicity</i></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Neutropenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">ANC 500 to 1,000/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Continue umbralisib; if ANC 500 to 1,000/mm<sup>3</sup> recurs (or is persistent), then withhold umbralisib until ANC is ≥1,000/mm<sup>3</sup>, then resume at the same dose. Consider supportive care as appropriate.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">ANC &lt;500/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold umbralisib until ANC is ≥500/mm<sup>3</sup>, then resume at the same dose. If ANC &lt;500/mm<sup>3 </sup>recurs, withhold umbralisib until ANC is ≥500/mm<sup>3</sup>, then resume at a reduced dose. Consider supportive care as appropriate.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Platelets 25,000 to &lt;50,000/mm<sup>3</sup> with bleeding <b>or</b> platelets &lt;25,000/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold umbralisib until platelets are ≥25,000/mm<sup>3 </sup>and bleeding (if applicable) resolves, then resume at the same dose.</p>
<p style="text-indent:0em;text-align:center;">If platelets 25,000 to &lt;50,000/mm<sup>3</sup> with bleeding <b>or</b> platelets &lt;25,000/mm<sup>3 </sup>recurs, withhold umbralisib until platelets are ≥25,000/mm<sup>3 </sup>and bleeding resolves (if applicable), then resume at a reduced dose.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Nonhematologic toxicity</i></p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:center;">Diarrhea or noninfectious colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Mild or moderate diarrhea (up to 6 stools/day over baseline) <b>or</b> asymptomatic (grade 1) colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">If persistent, withhold umbralisib until resolved, then resume at the same or reduced dose. If recurrence, withhold umbralisib until resolved, then resume at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Severe diarrhea (&gt;6 stools/day over baseline) <b>or</b> abdominal pain, stool with mucus or blood, change in bowel habits, peritoneal signs</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold umbralisib until resolved, then resume at a reduced dose. For recurrent severe diarrhea or recurrent colitis of any grade, discontinue umbralisib. Provide supportive care with antidiarrheals or enteric-acting steroids as indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Life-threatening</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue umbralisib. Provide supportive care with antidiarrheals or enteric-acting steroids as indicated.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:center;">Infection (including opportunistic infection)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold umbralisib until resolved, then resume at the same or reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">
<i>P. jirovecii</i> pneumonia (PCP)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">For suspected PCP, withhold umbralisib until evaluated. For confirmed PCP, discontinue umbralisib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Cytomegalovirus infection or viremia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold umbralisib until infection or viremia resolves, then resume at the same or reduced dose.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:center;">Severe cutaneous reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Severe</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold umbralisib until resolved, then resume at a reduced dose or discontinue. If recurrence after rechallenge, discontinue umbralisib. Evaluate all concomitant medications; if possible, discontinue those that may potentially contribute to cutaneous reactions. Administer supportive care as clinically necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Life-threatening</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue umbralisib. Administer supportive care as clinically necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (any grade)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue umbralisib. Administer supportive care as clinically necessary.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Severe</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold umbralisib until resolved, then resume at the same or reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Life-threatening</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue umbralisib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F55485050"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F55474736"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (19%), decreased appetite (19%), diarrhea (≤58%; severe diarrhea: ≤4%), nausea (38%), vomiting (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (27%; grades 3/4: 3%), neutropenia (≥15%; grade 3: 9%; grade 4: 9%), thrombocytopenia (26%; grades 3/4: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (33%), increased serum aspartate aminotransferase (32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (41%), insomnia (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (79%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (21%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Severe dermatological reaction (grade 3: 2%; including erythema of skin, maculopapular rash)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (2% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (grade ≥3: 10%), sepsis (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (7%), pneumonia (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Severe hepatotoxicity</p></div>
<div class="block coi drugH1Div" id="F55469356"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F55485034"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Serious neutropenia has occurred with umbralisib, including grade 3 and 4 cases. The median time to onset of ≥ grade 3 neutropenia was 45 days.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Serious cutaneous reactions, including grade 3 reactions and a fatal case of exfoliative dermatitis, have been reported with umbralisib. Grade 3 cutaneous reactions have included cases of exfoliative dermatitis, erythema, and rash (primarily maculopapular). The median time to ≥ grade 3 cutaneous reaction onset was 15 days (range: 9 days to 6.4 months). Evaluate all concomitant medications; discontinue those which may potentially contribute to cutaneous reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Serious diarrhea or noninfectious colitis has occurred with umbralisib; any grade diarrhea or colitis was reported in ~50% of patients, while grade 3 toxicity occurred in &lt;10%. The median time to any grade diarrhea or colitis was 1 month (range: 1 day to 23 months); 75% of cases occurred in the first 3 months of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serious hepatotoxicity has occurred with umbralisib, including grade 3 and 4 transaminase elevations. The median time to ≥ grade 3 AST and/or ALT elevations was 2.2 months (range: 15 days to 4.7 months).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious and fatal infections have occurred with umbralisib, including ≥ grade 3 infection. The most commonly reported ≥ grade 3 infections were pneumonia, sepsis, and urinary tract infections. The median time to onset of ≥ grade 3 infection was 2.4 months (range: 1 day to 21 months). Administer <i>Pneumocystis jirovecii</i> pneumonia (PCP) prophylaxis during umbralisib treatment. Consider antiviral prophylaxis to prevent cytomegalovirus (CMV) infection, including CMV reactivation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age experienced a higher incidence of serious adverse reactions (including infections) compared to patients &lt;65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Yellow dye: Umbralisib contains FD&amp;C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in some patients. Tartrazine sensitivity is frequently seen in patients who also have aspirin hypersensitivity.</p></div>
<div class="block prod-avail drugH1Div" id="F56836890"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">The manufacturer of Ukoniq, TG Therapeutics, has voluntarily withdrawn this product from sale. Limited distribution will occur through June 2022.</p></div>
<div class="block foc drugH1Div" id="F55480832"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tosylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ukoniq: 200 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #5 (tartrazine)]</p></div>
<div class="block geq drugH1Div" id="F55480830"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55533293"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ukoniq Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $159.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F55485029"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">For patients receiving a benefit from umbralisib treatment prior to its market withdrawal, the manufacturer planned to allow continued access via an expanded access program; contact the manufacturer, TG Therapeutics, for information.</p></div>
<div class="block adm drugH1Div" id="F55485057"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with food at the same time each day. Swallow whole; do not crush, break, cut, or chew.</p></div>
<div class="block hazard drugH1Div" id="F55485038"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Umbralisib may cause reproductive toxicity and teratogenicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F55476554"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Ukoniq: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F213176s000lbl.pdf%23page%3D19&amp;token=CKciBN1SiHGAB1QXOYWYd8NjSKFVA2ddJsOYsSpQFnIHb46eSqbOQdYEbTtyfjyCm6Hd6pSDArnPPOuJfZhEHo1gcoixprz1wSUJS%2F2XvWLGIUAvtAGkaSN42VNr1V5B&amp;TOPIC_ID=130727" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf#page=19</a></p></div>
<div class="block use drugH1Div" id="F55469355"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Updated findings from a clinical trial demonstrated safety concerns for umbralisib and as a result the FDA determined the risks of umbralisib treatment outweigh benefits; due to this, the manufacturer has voluntarily withdrawn umbralisib from the market.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Follicular lymphoma, relapsed or refractory: </b>Treatment of relapsed or refractory follicular lymphoma in adults who have received at least 3 prior lines of systemic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Marginal zone lymphoma, relapsed or refractory:</b> Treatment of relapsed or refractory marginal zone lymphoma in adults who have received at least 1 prior anti-CD20-based regimen.</p></div>
<div class="block mst drugH1Div" id="F55485028"><span class="drugH1">Medication Safety Issues</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sound-alike/look-alike issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Umbralisib may be confused with alpelisib, copanlisib, duvelisib, idelalisib, upadacitinib.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>High alert medication:</b></p>
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
<div class="block cyt drugH1Div" id="F55504473"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F55504470"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55485031"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation. Patients who may become pregnant should use effective contraception during therapy and for 1 month after the last dose of umbralisib. Patients with partners who may become pregnant should also use effective contraception during therapy and for 1 month after the last umbralisib dose.</p></div>
<div class="block pri drugH1Div" id="F55485032"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to umbralisib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F55485033"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if umbralisib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 1 month after the last umbralisib dose.</p></div>
<div class="block mop drugH1Div" id="F55485059"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC (obtain neutrophil counts at least every 2 weeks for the first 2 months and at least weekly if ANC &lt;1,000/mm<sup>3</sup>); liver function tests. Evaluate pregnancy status prior to treatment initiation in females of reproductive potential. Monitor for signs/symptoms of new or worsening infection (including <i>P. jirovecii</i> pneumonia [PCP] and cytomegalovirus [CMV]; if treatment is resumed following CMV infection, monitor for CMV reactivation by PCR or antigen test at least monthly), GI toxicity (diarrhea or noninfectious colitis), and severe cutaneous reactions (new or worsening). Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F55485040"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Umbralisib is a dual inhibitor of phosphatidylinositol-3-kinase-delta (PI3Kδ) and casein kinase 1 epsilon (CK1ε) with improved selectivity for the PI3Kδ isoform (Zinzani 2020). PI3Kδ is expressed in both normal and malignant B-cells; CK1ε may also be involved in the pathogenesis of cancer cells (including lymphoid malignancies). In vitro, umbralisib inhibited cell proliferation, CXCL12-mediated cell adhesion, and CCL19-mediated cell migration in lymphoma cell lines.</p></div>
<div class="block phk drugH1Div" id="F55485041"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Administration of a single umbralisib dose with a high-fat, high calorie meal (~917 calories with 171 calories from protein, 232 calories from carbohydrates, and 502 calories from fat) increased the umbralisib AUC and C<sub>max</sub> by 61% and 115%, respectively (compared to fasting conditions).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 312 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≥99.7%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via CYP2C9, CYP3A4, and CYP1A2.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 91 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: ~81% (17% as unchanged drug); urine: 3% (&lt;1% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 15.5 L/hour.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/umbralisib-united-states-withdrawn-from-market-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ukoniq (umbralisib) [prescribing information]. Edison, NJ: TG Therapeutics Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed February 6, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zinzani.1">
<a name="Zinzani.1"></a>Zinzani PL, Samaniego F, Jurczak W, et al. Umbralisib, the once daily dual inhibitor of PI3Kδ and casein kinase-1ε demonstrates clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 2 global unity-NHL trial. https://ash.confex.com/ash/2020/webprogram/Paper134851.html. Updated December 7, 2020. Accessed February 6, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 130727 Version 68.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
